Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5935/1678-9741.20120018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cerebral Hyperperfusion Syndrome After Carotid Revascularization; Predictors and Complications.
Ann Vasc Surg
March 2025
Center for Learning and Excellence in Vascular and Endovascular Surgery (CLEVER), Division of Vascular & Endovascular Surgery, Department of Surgery, UC San Diego (UCSD), San Diego, California.
Objectives: Cerebral hyperperfusion syndrome (CHS) is a rare but serious complication following carotid artery revascularization. Considering the varying rates observed among carotid endarterectomy (CEA), Transfemoral Carotid Artery Stenting (TFCAS), and Transcarotid Artery Revascularization (TCAR), identifying the predictors and complications of CHS is essential for improving patient outcomes. This study utilizes a national database to investigate the predictors and complications of CHS following carotid revascularizations.
View Article and Find Full Text PDFTriple antithrombotic therapy or 'triple therapy' describes the combination of 3 oral antithrombotic medications - an anticoagulant drug (warfarin, apixaban, rivaroxaban or dabigatran) and 2 antiplatelet drugs (usually aspirin plus clopidogrel). Most commonly, triple therapy is indicated for patients who require dual antiplatelet therapy following coronary stent insertion for acute coronary syndrome and long-term anticoagulation for atrial fibrillation. Current evidence supports shorter durations of triple therapy to mitigate bleeding risks without compromising ischaemic protection.
View Article and Find Full Text PDFAspirin plus clopidogrel versus cilostazol -based triple antiplatelet therapy in patients with ischemic heart disease undergoing PCI: a systematic review and meta-analysis of randomized controlled trials.
BMC Pharmacol Toxicol
February 2025
Department of Cardiology, National Heart and Lung Institute, Imperial College London, London, UK.
Introduction: Cilostazol has been widely used to prevent peripheral vascular events after PCI. However, guidelines in cilostazol-based triple antiplatelet therapy for patients with ischemic heart disease undergoing PCI remain unclear. The purpose of this study was to assess the efficacy and safety of DAPT (aspirin and clopidogrel) compared to cilostazol -based TAPT (aspirin, clopidogrel and cilostazol).
View Article and Find Full Text PDFWhen the Shaft Breaks: Managing a Cath Lab Nightmare.
JACC Case Rep
February 2025
Serviço de Cardiologia, Departamento de Coração e Vasos, Centro Hospitalar Universitário de Lisboa Norte Hospital de Santa Maria, Av Prof Egas Moniz, Lisboa, Portugal.
Objective: We describe the case of a 57-year-old male patient with anterior ST-segment elevation myocardial infarction in cardiogenic shock. Coronary angiography revealed severe left main (LM) and triple-vessel disease, and the patient was refused for surgery due to lack of distal grafting landing zone. A shaft fracture occurred during LM percutaneous coronary intervention, leaving the fractured stent hanging in the aorta.
View Article and Find Full Text PDFEffect of Intravascular Ultrasonography (IVUS) Imaging on Stent Optimization in Patients Achieving Optimal Results After Angiographic-Guided Stent Implantation: A Non-randomized Interventional Study.
Cureus
January 2025
Department of Cardiology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND.
Background: Angiography possesses limitations in assessing plaque composition, vessel width, diffuse reference vessel disease, lesion severity, and the success or failure of stent placement. Intravascular ultrasonography (IVUS) helps address several of these issues by offering enhanced visualization of the coronary architecture and stent placement.
Methods: This study was conducted at the Department of Cardiology of All India Institute of Medical Sciences, Rishikesh.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!